Similar articles

• New drug-eluting stents with biodegradable polymers.

  Van Der Giessen WJ, Van Beusekom HM. Van Der Giessen WJ, et al. Minerva Cardioangiol. 2011 Feb;59(1):31-8. Minerva Cardioangiol. 2011. PMID: 21285929
• Encouraging data from ABSORB IV pave the way to new scaffolds.

  Colombo A, Giannini F. Colombo A, et al. Lancet. 2018 Oct 27;392(10157):1490-1491. doi: 10.1016/S0140-6736(18)32319-5. Epub 2018 Sep 25. Lancet. 2018. PMID: 30266413 No abstract available.
• Impact of lesion calcification on angiographic outcomes after Absorb everolimus-eluting bioresorbable vascular scaffold implantation: an observation from the ABSORB Japan trial.

  Ohya M, Kadota K, Sotomi Y, Kozuma K, Tanabe K, Uematsu M, Kawasaki T, Morino Y, Tobaru T, Nakao K, Tachibana K, Kishi K, Shibata Y, Ying S, Kusano H, Stone GW, Popma JJ, Onuma Y, Serruys PW, Kimura T. Ohya M, et al. EuroIntervention. 2017 Feb 20;12(14):1738-1746. doi: 10.4244/EIJ-D-16-00359. EuroIntervention. 2017. PMID: 27821375 Clinical Trial.
• Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.

  Sotomi Y, Suwannasom P, Tenekecioglu E, Tateishi H, Abdelghani M, Serruys PW, Onuma Y. Sotomi Y, et al. Expert Rev Cardiovasc Ther. 2015 Oct;13(10):1127-45. doi: 10.1586/14779072.2015.1089172. Expert Rev Cardiovasc Ther. 2015. PMID: 26401921 Review.
• From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI.

  Tenekecioglu E, Bourantas C, Abdelghani M, Zeng Y, Silva RC, Tateishi H, Sotomi Y, Onuma Y, Yılmaz M, Serruys PW. Tenekecioglu E, et al. Expert Rev Med Devices. 2016;13(3):271-86. doi: 10.1586/17434440.2016.1143356. Epub 2016 Feb 12. Expert Rev Med Devices. 2016. PMID: 26782080 Review.